Anamorelin

Research Use Only: This page is for research and educational purposes only. It does not provide medical advice, treatment instructions, or guaranteed outcome claims.

What Is Anamorelin?

Anamorelin (ONO-7643) is a synthetic, orally active ghrelin receptor agonist developed for the treatment of cancer-related cachexia — a debilitating syndrome of involuntary weight loss, muscle wasting, and appetite loss that affects an estimated 50–80% of advanced cancer patients. Unlike endogenous ghrelin, which has a half-life of minutes, anamorelin was designed for once-daily oral administration with sustained receptor activation.[1]

Anamorelin received regulatory approval in Japan in 2021 for cancer cachexia in patients with non-small cell lung cancer (NSCLC), gastric cancer, pancreatic cancer, and colorectal cancer — making it one of very few peptide-derived therapeutics with a specific cachexia indication.[2] It has not been approved by the FDA or EMA, though clinical trials have been conducted in multiple countries.

Compound Profile

What Does Anamorelin Actually Do?

Anamorelin research has established it as an appetite-stimulating and anabolic agent acting through the growth hormone secretagogue receptor (GHS-R1a). In the ROMANA phase III clinical trials — the largest studies of any ghrelin agonist in cachexia — anamorelin significantly increased lean body mass and body weight compared to placebo in NSCLC patients with cachexia.[1]

The dual action profile — appetite stimulation plus growth hormone release — distinguishes anamorelin from simple appetite enhancers. By activating the same receptor as endogenous ghrelin, anamorelin simultaneously increases food intake through hypothalamic appetite circuits and stimulates growth hormone secretion through pituitary pathways, addressing both the caloric deficit and catabolic components of cachexia.[3]

How Anamorelin Works

Anamorelin acts as a selective agonist at the growth hormone secretagogue receptor 1a (GHS-R1a), the same receptor targeted by endogenous ghrelin. GHS-R1a is a G protein-coupled receptor expressed in the hypothalamus, pituitary, and peripheral tissues. Receptor activation triggers two parallel downstream cascades.[1][3]

In the hypothalamus, GHS-R1a activation stimulates orexigenic (appetite-promoting) neurons in the arcuate nucleus, increasing NPY/AgRP signalling and suppressing anorexigenic POMC pathways. This produces sustained appetite stimulation — a critical effect in cachexia patients who experience profound anorexia.[3]

In the anterior pituitary, GHS-R1a activation on somatotrophs stimulates growth hormone (GH) release through pathways that are synergistic with, but independent of, the hypothalamic GHRH pathway. The resulting GH increase drives IGF-1 production, which in turn supports anabolic processes including protein synthesis and lean tissue maintenance. This mechanism connects anamorelin to the broader GH secretagogue peptide class that includes GHRP-2, GHRP-6, and Hexarelin.

Appetite & Weight Management Context

Anamorelin’s primary clinical application directly addresses appetite and weight management — specifically in the context of cancer-related appetite loss and involuntary weight decline. The ROMANA trials demonstrated statistically significant increases in body weight and lean body mass over 12 weeks of treatment.[1]

In the Japanese phase II trial, anamorelin at 100mg daily produced significant increases in body weight, lean body mass, and appetite scores compared to placebo in NSCLC patients. The appetite-stimulating effect was consistent and clinically meaningful, with patients reporting improved food intake and quality of life metrics related to eating.[5]

However, a critical limitation emerged across trials: while anamorelin consistently improved body composition endpoints, it did not significantly improve handgrip strength — a measure of functional muscle capacity. This dissociation between mass and function has been a central point of regulatory and clinical discussion.[1] See the Appetite & Weight Management goal page for broader context.

Muscle Growth Context

Anamorelin’s effects on lean body mass place it within the muscle growth research context, though with important caveats. The ROMANA trials showed significant lean mass gains (+0.95 to +1.15 kg over placebo at 12 weeks), which is meaningful in a catabolic disease context but distinct from hypertrophy research in healthy populations.[1]

The anabolic mechanism operates through GH/IGF-1 axis stimulation rather than direct myotropic effects. Anamorelin increases circulating GH and IGF-1 levels, which support protein synthesis and nitrogen retention — pathways shared with other GH secretagogues like GHRP-2 and Ipamorelin.[3]

The disconnect between lean mass gains and functional strength improvements is not fully explained. Hypotheses include insufficient study duration, the possibility that gained mass is not fully contractile tissue, or that neuromuscular function deficits in cachexia require different interventions. Compare with GHRP-2 and GHRP-6 for related GH secretagogue profiles, or see the Muscle Growth goal page.

Metabolic Health / Insulin Sensitivity Context

Ghrelin receptor activation has established effects on metabolic regulation, placing anamorelin within the metabolic health research context. GHS-R1a signalling influences glucose homeostasis, lipid metabolism, and energy balance through both central and peripheral pathways.[3]

In clinical trials, anamorelin’s metabolic effects have been characterised primarily through GH and IGF-1 changes rather than direct metabolic endpoints. GH elevation can affect glucose metabolism (GH is counter-regulatory to insulin), though clinically significant glucose disturbances were not reported as common adverse events in the ROMANA trials.[1]

The metabolic context of anamorelin is complex because its primary target population — cachexia patients — already has profoundly disrupted metabolism. Whether anamorelin’s metabolic effects would differ in non-cachexia contexts is unknown. See the Metabolic Health goal page for broader context.

Anamorelin Benefits

• Oral bioavailability: Unlike most peptide-based GH secretagogues that require injection, anamorelin is orally active — a significant practical advantage for chronically ill patient populations.[1]
• Clinically proven appetite stimulation: Phase III trials demonstrated significant, sustained appetite increases in cancer cachexia patients — one of very few compounds with robust clinical evidence for this indication.[1][5]
• Lean mass preservation: ROMANA trials showed significant lean body mass increases over placebo, addressing the muscle-wasting component of cachexia.[1]
• Regulatory validation: Japanese approval for cancer cachexia provides regulatory-level evidence review — a level of validation that most research peptides lack entirely.[2]
• Dual mechanism: Simultaneous appetite stimulation and GH/IGF-1 axis activation addresses both reduced intake and increased catabolism in cachexia.[3]

Anamorelin Side Effects

Anamorelin has a more established safety profile than most research peptides, thanks to Phase III clinical trial data. The ROMANA trials reported the following adverse events:

• Glycaemic effects: GH-mediated increases in blood glucose were observed. Diabetes mellitus or glucose intolerance was reported in a small percentage of patients, consistent with GH’s counter-regulatory metabolic effects.
• Hepatic effects: Transient elevations in liver enzymes (AST, ALT) were reported in some trial participants, typically mild and reversible.
• Cardiac QT effects: Anamorelin has a known QTc-prolonging potential, which contributed to regulatory concerns in markets outside Japan. A case report documented reversible ST-T segment changes associated with anamorelin use.[6]
• Gastrointestinal effects: Nausea and constipation were reported at rates modestly above placebo.
• Overall tolerability: In the ROMANA trials, discontinuation rates due to adverse events were comparable between anamorelin and placebo groups, suggesting generally acceptable tolerability.[1]

Half-Life

Anamorelin has a plasma half-life of approximately 7–12 hours, supporting once-daily oral dosing. This extended half-life compared to endogenous ghrelin (~10–30 minutes) or injectable GH secretagogues like GHRP-2 (~15–30 minutes) is a key pharmacological advantage.[3]

The oral bioavailability and sustained half-life were achieved through peptidomimetic design — anamorelin is technically a small molecule that mimics ghrelin’s receptor interaction rather than a traditional peptide. This structural approach bypasses the gastrointestinal degradation and poor absorption that limit most peptide therapeutics.

Limits of Current Evidence

• No FDA/EMA approval: Despite positive phase III trial results, anamorelin has not been approved outside Japan, partly due to concerns about the lean mass vs. function disconnect and QTc effects.
• Function gap: The consistent failure to improve handgrip strength despite lean mass gains is an unresolved limitation. Whether longer treatment durations or combination with exercise would close this gap is unknown.[1]
• Disease-specific evidence: Clinical trial data is almost entirely in cancer cachexia populations. Extrapolation to other wasting conditions or healthy populations is unsupported.
• Long-term safety unknown: Trial durations were 12–24 weeks. Long-term effects of sustained GHS-R1a agonism, particularly on glucose metabolism and cardiac conduction, require further study.
• Publication and industry bias: Anamorelin development was industry-sponsored, and trial reporting should be interpreted with standard considerations for industry-funded research.

Verdict

Anamorelin stands apart from most peptides on this site by virtue of having genuine phase III clinical trial evidence and regulatory approval — a rarity in the peptide research landscape. The ROMANA trials were well-designed, adequately powered, and met their primary endpoints for lean body mass. The Japanese regulatory approval validates both the efficacy signal and the acceptable safety profile for its indicated population.

The critical limitation — failure to translate lean mass gains into functional strength improvements — is important and honest to acknowledge. Whether this reflects a biological ceiling of ghrelin agonism, inadequate study duration, or the need for combined pharmacological and physical interventions remains an active research question. For cancer cachexia specifically, anamorelin represents the most clinically validated ghrelin-pathway intervention available.

FAQ

What is anamorelin?

Anamorelin (ONO-7643) is a synthetic, orally active ghrelin receptor agonist developed for cancer cachexia treatment. It stimulates appetite and increases lean body mass through the same receptor targeted by the endogenous hunger hormone ghrelin. It is approved in Japan for cachexia in several cancer types.

Is anamorelin approved by the FDA?

No. Anamorelin is approved only in Japan (2021) for cancer cachexia in NSCLC, gastric, pancreatic, and colorectal cancer patients. It has not received FDA or EMA approval, partly due to regulatory concerns about the dissociation between lean mass gains and functional strength improvements.

How does anamorelin differ from ghrelin?

While both activate the GHS-R1a receptor, anamorelin is a synthetic peptidomimetic with oral bioavailability and a half-life of 7–12 hours, compared to ghrelin’s half-life of approximately 10–30 minutes. Anamorelin can be taken as a once-daily oral tablet, whereas ghrelin requires injection.

What is cancer cachexia?

Cancer cachexia is a multi-organ syndrome characterised by involuntary weight loss, skeletal muscle wasting, and reduced appetite that cannot be fully reversed by conventional nutritional support. It affects an estimated 50–80% of advanced cancer patients and is associated with reduced treatment tolerance and survival.

Does anamorelin build muscle?

Clinical trials showed anamorelin increases lean body mass compared to placebo in cancer cachexia patients. However, this lean mass gain did not translate into improved handgrip strength — suggesting the relationship between mass and function is more complex than simple tissue accretion.[1]

What are the side effects of anamorelin?

Reported side effects from clinical trials include mild blood glucose elevation, transient liver enzyme increases, potential QTc prolongation, and gastrointestinal symptoms (nausea, constipation). Overall discontinuation rates due to adverse events were comparable to placebo in the ROMANA trials.

References

1. Temel JS, et al. Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomised, double-blind, phase 3 trials. Lancet Oncol. 2016. PMID: 26906526
2. Wakabayashi H, et al. The regulatory approval of anamorelin for treatment of cachexia in patients with non-small cell lung cancer, gastric cancer, pancreatic cancer, and colorectal cancer. J Cachexia Sarcopenia Muscle. 2021. PMID: 33382205
3. Currow DC, et al. The emerging role of anamorelin hydrochloride in the management of patients with cancer anorexia-cachexia. Future Oncol. 2017. PMID: 28621564
4. Nishie K, et al. Anamorelin for advanced non-small-cell lung cancer with cachexia: Systematic review and meta-analysis. Lung Cancer. 2017. PMID: 29191597
5. Takayama K, et al. Anamorelin (ONO-7643) in Japanese patients with non-small cell lung cancer and cachexia: results of a randomized phase 2 trial. Support Care Cancer. 2016. PMID: 27005463
6. Akaishi H, et al. Reversible ST-T Segment Changes Induced by Anamorelin: A Case Report. Respirol Case Rep. 2025. PMID: 41211336